Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT-4 KarXT for psychosis associated with Alzheimer's disease
jRCT2051240245Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease psychosis (ADP) comparing KarXT arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions score. Started Jan 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease psychosis (ADP)
Beyond the preview
Go deeper on jRCT2051240245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240245.